Literature DB >> 25603416

C-reactive protein polymorphisms influence serum CRP-levels independent of disease activity in ankylosing spondylitis.

Theodora A M Claushuis1, Mirjam K de Vries1, Mignon A C van der Weijden1, Ingrid M Visman2, Michael T Nurmohamed2, Jos W R Twisk3, Irene E Van der Horst-Bruinsma1, Jakob B A Crusius4.   

Abstract

OBJECTIVES: C-reactive protein (CRP) levels are frequently used to determine disease activity in patients with ankylosing spondylitis (AS), but these levels may not reflect disease activity. We therefore investigated the influence of common single-nucleotide polymorphisms (SNPs) in the CRP gene on CRP levels in AS patients. Additionally, the relation between CRP levels and BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) was examined.
METHODS: This exploratory cross-sectional study included 189 Dutch AS patients. CRP SNPs rs2794521, rs3091244, rs1800947 and rs876538 were genotyped and haplotypes constructed. Linear regression analysis was used for the association between SNPs and CRP levels, with correction for confounders non-steroidal anti-inflammatory drugs use, body mass index, smoking, age, gender and disease activity (BASDAI).
RESULTS: Only 52% of AS patients with a high disease activity (BASDAI ≥4) showed a high CRP level (≥10mg/L), whereas the others did not. In AS patients, CRP levels changed with different genotypes, with genotype CA of tri-allelic (C>T>A) SNP rs3091244 showing higher CRP levels in comparison with genotype CC (CA: 18.6 mg/L vs. CC: 8.3 mg/L; p=0.02). Carriers of haplotype 5 (tagged by allele A of rs3091244) had a higher risk to express a CRP ≥10 mg/L (OR=2.9, 95%CI 1.0-8.3; p=0.05) when compared with non-carriers.
CONCLUSIONS: In AS, patients with high disease activity often do not show corresponding high CRP levels. We found that CRP levels vary with different CRP genotype in AS patients. Carrying distinct genetic variants might play a role in certain AS patients who show low CRP levels despite high disease activity (as well as high CRP levels with low disease activity). This observation may be important for the interpretation of disease activity scores that incorporate CRP levels, like the ASDAS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25603416

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

1.  Biomechanical evaluation of cornea in patients with ankylosing spondylitis.

Authors:  Mehtap Caglayan; Ozge Sarac; Pinar Kosekahya; Sukran Erten; Berna Ayan; Nurullah Cagil
Journal:  Int Ophthalmol       Date:  2016-10-05       Impact factor: 2.031

2.  The effects of total hip arthroplasty in treating hip bony fusion in young and middle-aged patients with ankylosing spondylitis.

Authors:  Hong-Zhang Guo; Chen-Xu Yang; Zhao-Peng Tang; Cheng-Xiang Wang
Journal:  J Orthop Surg Res       Date:  2019-08-08       Impact factor: 2.359

3.  Association between C-reactive protein gene variant and treatment efficacy of etanercept in ankylosing spondylitis patients receiving hip arthroplasty.

Authors:  Yuansheng Xu; Wei Jiang; Hui Zhang
Journal:  J Clin Lab Anal       Date:  2020-04-20       Impact factor: 2.352

4.  Serum progranulin levels in axial spondyloarthropathy and relationship with clinical features.

Authors:  Didem İldemir Doğangün; Meliha Kasapoğlu Aksoy; Lale Altan
Journal:  Arch Rheumatol       Date:  2021-10-16       Impact factor: 1.007

5.  Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice.

Authors:  Chrysoula G Gialouri; Gerasimos Evangelatos; Maria Pappa; Anastasios Karamanakos; Alexios Iliopoulos; Maria G Tektonidou; Petros P Sfikakis; George E Fragoulis
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-05       Impact factor: 3.625

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.